90-Second Read: Hantavirus cases spark surge in pharma and biotech stocks — here’s why

The outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms developing vaccines. The World Health Organization flagged an outbreak of Hantavirus, a fatal and viral respiratory disease spread by rodents, on May 2, after some passengers caught it on a Dutch-flagged expedition cruise ship, the MV Hondius, which was sailing the Atlantic. WHO's Director General Tedros Adhanom Ghebreyesus said Friday that eight cases have been reported so far, with three deaths, and five of the cases confirmed as Hantavirus. An outbreak of the Hantavirus caused a brief spike in the stocks of companies working to develop a vaccine, but the stocks weren't able to sustain their early gains.

With regards to current headlines, we see no meaningful revenue opportunity." "Hantavirus is a low-incidence, structurally small market, and we view any potential outsized moves as sentiment-driven, not fundamental. Meanwhile, vaccine development firm Inovio Pharmaceuticals fell 1%, while biotech firms Novavax and Emergent BioSolutions each fell 5% and 1%, respectively. Passengers and crew have begun disembarking under strict health protocols, with authorities coordinating testing, isolation, and repatriation efforts across multiple countries as they continue to monitor the spread of the virus. The MV Hondius has now docked in Tenerife in Spain's Canary Islands, after spending several days offshore awaiting clearance.

The public health risk for the virus is low, according to the WHO and other health authorities that have noted human transmission is rare. Shares had spiked as high at $59.48 earlier in the session. President Donald Trump has said the cruise ship outbreak is under control and that a report on the virus would follow soon. Data is a real-time snapshot *Data is delayed at least 15 minutes.